Change of right ventricular systolic pressure can indicate dasatinib‐induced pulmonary arterial hypertension in chronic myeloid leukemia-Reference-Cited by-同舟云学术

Change of right ventricular systolic pressure can indicate dasatinib‐induced pulmonary arterial hypertension in chronic myeloid leukemia

Published:2021-02-15 Issue:5 Volume:10 Page:1515-1524
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Lee Sung‐Eun¹^ORCID,Hyun Kong Jee²,Kim Soo‐Hyun³,Jang Eun‐Jung³,Chung Nack‐Gyun⁴,Cho Bin⁴,Joong Oh Suk⁵,Jung Hae‐Eok⁶,Youn Ho‐Joong⁶,Chung Woo‐Baek⁶^ORCID,Kim Dong‐Wook¹³

Affiliation:

1. Department of Hematology Catholic Hematology HospitalCollege of MedicineThe Catholic University of Korea Seoul South Korea

2. Division of Hematology Department of Internal Medicine Wonju Christian HospitalYonsei University College of Medicine Wonju South Korea

3. Leukemia Research InstituteThe Catholic University of Korea Seoul South Korea

4. Department of Pediatrics Catholic Hematology HospitalCollege of MedicineThe Catholic University of Korea Seoul South Korea

5. Department of Hematology Kangbuk Samsung HospitalSungkyunkwan University School of Medicine Seoul South Korea

6. Division of Cardiology College of MedicineThe Catholic University of Korea Seoul South Korea

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3588

Reference29 articles.

1. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)

2. Dasatinib-induced pulmonary arterial hypertension

3. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia

4. Pulmonary Arterial Hypertension Caused by Treatment with Dasatinib for Chronic Myeloid Leukemia -Critical Alert-

5. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An association between Dasatinib, elevated left atrial pressure and pleural effusion;International Journal of Cardiology;2024-09

2. Cancer Therapy-Associated Pulmonary Hypertension and Right Ventricular Dysfunction: Etiologies and Prognostic Implications;Reviews in Cardiovascular Medicine;2024-03-05

3. Cardio-Oncology Guidelines and Strength of the Evidence;JACC: CardioOncology;2023-02